Alibaba Health Information Technology (Alibaba Health Information Technology) Risk Assessment

View and export this data going back to 2015. Start your Free Trial

What is Alibaba Health Information Technology Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Alibaba Health Information Technology is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Alibaba Health Information Technology's Risk Assessment

For the Pharmaceutical Retailers subindustry, Alibaba Health Information Technology's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alibaba Health Information Technology's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Alibaba Health Information Technology's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Alibaba Health Information Technology's Risk Assessment falls into.

Alibaba Health Information Technology (OTCPK:ALBHF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Alibaba Health Information Technology Risk Assessment Related Terms

Thank you for viewing the detailed overview of Alibaba Health Information Technology's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Alibaba Health Information Technology (Alibaba Health Information Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Alibaba Health Information Technology Ltd (OTCPK:ALBHF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ALBBY:USA 00241:Hong Kong TWYA:Germany TWY:Germany TWY:Germany

Address

Guanghua Road, 65/F, CITIC Tower, Building 1, No.10, Jianwai Subdistrict, Chaoyang District, Beijing, CHN

Website

https://www.alihealth.cn

Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba's Tmall app and Alipay. The company also provides online consultation services in a separate app called Yilu or "Dr. Deer", although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 97% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.